Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.

IF 5.4 2区 医学 Q1 Medicine Journal of Endocrinological Investigation Pub Date : 2024-12-01 Epub Date: 2024-05-24 DOI:10.1007/s40618-024-02396-1
E Varaldo, N Prencipe, C Bona, D Cuboni, L S Aversa, M Sibilla, F Bioletto, A M Berton, C Gramaglia, V Gasco, E Ghigo, S Grottoli
{"title":"Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.","authors":"E Varaldo, N Prencipe, C Bona, D Cuboni, L S Aversa, M Sibilla, F Bioletto, A M Berton, C Gramaglia, V Gasco, E Ghigo, S Grottoli","doi":"10.1007/s40618-024-02396-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cabergoline (CAB) has shown to have benefic effects on the metabolism in different clinical settings but its metabolic role in acromegaly disease has not been studied yet. Aim of our study was to evaluate the impact of CAB on glucose metabolism and weight in patients with acromegaly.</p><p><strong>Methods: </strong>All patients with acromegaly undergoing continuous treatment with CAB for at least 6 months were retrospectively screened. Exclusion criteria were discontinuation of CAB for more than one month, change of antidiabetic or other therapy for acromegaly, concomitant untreated hormonal deficiency, initiation of pregnancy and/or breastfeeding. All patients were evaluated in terms of biochemical disease control, glucose metabolism and weight at baseline (T0) and after the introduction of CAB therapy at 6 (T6) and 12 months (T12).</p><p><strong>Results: </strong>Twenty-six patients (15 females and 11 males) were evaluated at T0 and T6 and 19 patients (12 females and 7 males) were also evaluated at T12. Insulin-like growth factor I (IGF-I) and prolactin (PRL) levels were significantly lower at T6 and T12 compared to baseline (p < 0.001 for IGF-I, p < 0.05 for PRL) even if no further differences were observed between T12 and T6. Considering the entire cohort, no differences were appreciated regarding the metabolic parameters but a significant reduction in weight and body mass index (BMI) was observed at both T6 (p = 0.009 for weight, p = 0.021 for BMI) and T12 (p = 0.014 for weight, p = 0.017 for BMI) compared to baseline.</p><p><strong>Conclusion: </strong>Our results confirm the efficacy of CAB in providing a significant improvement in the biochemical disease control but do not demonstrate a marked benefit on glucose metabolism of acromegaly patients. In such patients, CAB appears to have a rapid effect on weight and BMI, with significant changes noticeable as early as 6 months and persisting for at least 12 months.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinological Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40618-024-02396-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Cabergoline (CAB) has shown to have benefic effects on the metabolism in different clinical settings but its metabolic role in acromegaly disease has not been studied yet. Aim of our study was to evaluate the impact of CAB on glucose metabolism and weight in patients with acromegaly.

Methods: All patients with acromegaly undergoing continuous treatment with CAB for at least 6 months were retrospectively screened. Exclusion criteria were discontinuation of CAB for more than one month, change of antidiabetic or other therapy for acromegaly, concomitant untreated hormonal deficiency, initiation of pregnancy and/or breastfeeding. All patients were evaluated in terms of biochemical disease control, glucose metabolism and weight at baseline (T0) and after the introduction of CAB therapy at 6 (T6) and 12 months (T12).

Results: Twenty-six patients (15 females and 11 males) were evaluated at T0 and T6 and 19 patients (12 females and 7 males) were also evaluated at T12. Insulin-like growth factor I (IGF-I) and prolactin (PRL) levels were significantly lower at T6 and T12 compared to baseline (p < 0.001 for IGF-I, p < 0.05 for PRL) even if no further differences were observed between T12 and T6. Considering the entire cohort, no differences were appreciated regarding the metabolic parameters but a significant reduction in weight and body mass index (BMI) was observed at both T6 (p = 0.009 for weight, p = 0.021 for BMI) and T12 (p = 0.014 for weight, p = 0.017 for BMI) compared to baseline.

Conclusion: Our results confirm the efficacy of CAB in providing a significant improvement in the biochemical disease control but do not demonstrate a marked benefit on glucose metabolism of acromegaly patients. In such patients, CAB appears to have a rapid effect on weight and BMI, with significant changes noticeable as early as 6 months and persisting for at least 12 months.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卡麦角林对肢端肥大症患者体重和糖代谢的影响。
目的:卡麦角林(CAB)在不同的临床环境中对新陈代谢有益处,但其在肢端肥大症中的代谢作用尚未被研究。我们的研究旨在评估 CAB 对肢端肥大症患者糖代谢和体重的影响:回顾性筛选所有接受 CAB 连续治疗至少 6 个月的肢端肥大症患者。排除标准为停用 CAB 超过一个月、更换了抗糖尿病或其他治疗肢端肥大症的疗法、同时存在未治疗的激素缺乏症、开始妊娠和/或哺乳。对所有患者在基线(T0)和接受 CAB 治疗后 6 个月(T6)和 12 个月(T12)的生化疾病控制、糖代谢和体重进行了评估:对 26 名患者(15 名女性和 11 名男性)进行了 T0 和 T6 评估,对 19 名患者(12 名女性和 7 名男性)进行了 T12 评估。与基线相比,胰岛素样生长因子 I(IGF-I)和催乳素(PRL)水平在 T6 和 T12 时明显降低(p 结论:我们的研究结果证实了胰岛素样生长因子 I(IGF-I)和催乳素(PRL)的疗效:我们的研究结果证实了 CAB 在显著改善肢端肥大症患者生化疾病控制方面的疗效,但并未证明 CAB 对肢端肥大症患者的糖代谢有明显益处。在这类患者中,CAB 似乎对体重和体重指数(BMI)有快速影响,最早在 6 个月时就有明显变化,并持续至少 12 个月。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Endocrinological Investigation
Journal of Endocrinological Investigation ENDOCRINOLOGY & METABOLISM-
CiteScore
8.10
自引率
7.40%
发文量
242
期刊介绍: The Journal of Endocrinological Investigation is a well-established, e-only endocrine journal founded 36 years ago in 1978. It is the official journal of the Italian Society of Endocrinology (SIE), established in 1964. Other Italian societies in the endocrinology and metabolism field are affiliated to the journal: Italian Society of Andrology and Sexual Medicine, Italian Society of Obesity, Italian Society of Pediatric Endocrinology and Diabetology, Clinical Endocrinologists’ Association, Thyroid Association, Endocrine Surgical Units Association, Italian Society of Pharmacology.
期刊最新文献
Correction to: The diagnosis of hypophosphatasia in children as a multidisciplinary effort: an expert opinion. TFCP2L1, a potential differentiation regulator, predicts favorable prognosis and dampens thyroid cancer progression. The complexity of glucose time series is associated with short- and long-term mortality in critically ill adults: a multi-center, prospective, observational study. Total osteocalcin levels are independently associated with worse testicular function and a higher degree of hypothalamic-pituitary-gonadal axis activation in Klinefelter syndrome. Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1